Skip to content
Disclosery

AJU IB Investment Co., Ltd.

Follow

13F filer, CIK 1710065, Seoul, Korea Republic of

AJU IB Investment Co., Ltd. reported $30,523,310 across 6 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001140361-26-019665

Period
2026-03-31
Reported value
$30.5M
Holdings
6
Top 10 weight
100%
New
2
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RLYBnew+94,334$846K
XLOnew+47,695$401K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RALLYBIO CORPexited-754,678-$4.14M
XLOexited-667,742-$427K
RAPT THERAPEUTICS INCexited-12,437-$421K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001140361-26-019665, largest first. % of portfolio is the value over $30,523,310, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 1,047,557 shares; 2025Q1: 1,047,557 shares; 2025Q2: 1,047,557 shares; 2025Q3: 1,047,557 shares; 2025Q4: 223,486 shares; 2026Q1: 223,486 shares 223,486$25.7M84.07%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 457,059 shares; 2025Q1: 457,059 shares; 2025Q2: 457,059 shares; 2025Q3: 457,059 shares; 2025Q4: 19,648 shares; 2026Q1: 19,648 shares 19,648$1.64M5.36%0Timeline
SEERSEER INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 816,375 shares; 2025Q1: 816,375 shares; 2025Q2: 816,375 shares; 2025Q3: 816,375 shares; 2025Q4: 816,375 shares; 2026Q1: 816,375 shares 816,375$1.54M5.05%0Timeline
RLYBRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 94,334 shares 94,334$846K2.77%newTimeline
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 175,000 shares; 2025Q1: 175,000 shares; 2025Q2: 175,000 shares; 2025Q3: 175,000 shares; 2025Q4: 17,500 shares; 2026Q1: 17,500 shares 17,500$436K1.43%0
XLOXILIO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 47,695 shares 47,695$401K1.31%newTimeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RALLYBIO CORPRALLYBIO CORP754,678$4.14Mshares
XLOXilio Therapeutics Inc.667,742$427Kshares
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC12,437$421Kshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001140361-26-019665 base2026-05-08acceptance time not in the bulk data set